Fibroblast growth factor receptor 2 (FGFR2) belongs to the FGFR family, which plays an important role in cell growth, invasiveness, motility and angiogenesis. In human breast cancer, expression of FGFR2 is estrogen receptor (ER)-dependent and correlates with a lower rate of apoptosis. Recently, whole-genome association studies have identified several single-nucleotide polymorphisms (SNPs) of FGFR2 as novel breast cancer susceptibility loci. In the present study of 1049 breast cancer patients and 1073 cancer-free controls, we assessed whether polymorphisms of FGFR2 are associated with breast cancer risk in Chinese women and whether these associations are stronger in women with a reproductive history suggestive of greater exposure to endogenous estrogens. We genotyped three FGFR2 polymorphisms (rs2981582C/T, rs1219648A/G and rs2420946C/T) using the SNPstream 12-plex platform. Each of the three SNPs was significantly associated with increased breast cancer risk in a dosedependent manner. Compared with women with 0-2 risk loci, those with 3 risk loci had a 1.36-fold increased odds of breast cancer (95% confidence interval 5 1.13-1.62, P 5 0.001). In stratified analyses, associations between the presence of 3 risk loci and breast cancer were stronger among women with ER-and/or progesterone receptor-positive cancers, premenopausal women and women with an older age at first live birth. Furthermore, there was a significant additive interaction between risk genotypes and menopausal status (P for multiplication interaction/additive interaction: 0.083/0.037). These findings indicate that genetic variants in FGFR2 may contribute to breast cancer occurrence in Chinese women, possibly through pathways related to estrogen and/or progesterone.
Introduction
Breast cancer is the most commonly occurring cancer and the leading cause of cancer death among women worldwide, accounting for 23% of all cancers and .400 000 deaths annually (1) . In China, the incidence rate of breast cancer has increased dramatically in recent years, with a sharp rise of 38.5% between 2000 and 2005 (2) . The etiology of breast cancer appears to entail a complex combination of genetic, environmental and lifestyle factors; of these, menstrual and reproductive factors, such as earlier menarche, nulliparity, later age at first birth and later menopause, have a dominant relation to risk (3) (4) (5) . In developing countries, breast cancer tends to be diagnosed at an earlier age than in European and American population, and the rapid rate of increase in incidence before menopause is not maintained afterwards, possibly reflecting diminished levels of circulating estrogens (5) .
Twin-and family-based studies indicate that a substantial proportion of breast cancer is due to inherited susceptibility, but only a small fraction of cases are associated with inherited mutations of known high-penetrance genes (e.g. BRCA1, BRCA2, ATM, etc.). Common variants in other lower penetrance genes may be more important and may account for higher attributable risks (6) . Recently, a largescale genome-wide association study (7) identified five new independent low-penetrance susceptibility loci that were strongly associated with breast cancer in populations of diverse ethnicity. Four of these [fibroblast growth factor receptor 2 (FGFR2), TNRC9, MAP3K1 and LSP1] contain plausible causative genes, among which FGFR2 has a prior relevance to breast cancer.
FGFR2 belongs to the FGFR family, which contributes to cell growth, invasiveness, motility and angiogenesis (8) . Overexpression of FGFR2 is observed in breast cancer cell lines (9) , as well as in breast tumor tissues (10) . The FGFR2 gene, located at chromosome 10q26, contains at least 22 exons (11) . Recently, Easton et al. (7) found that rs2981582 in intron 2 of FGFR2 was associated with an increased risk of breast cancer in a two-stage genome-wide association study among 4398 cases and 4316 controls, followed by a third stage of 21 860 cases and 22 578 controls from 22 studies. In addition, in a genome-wide association study of 1145 post-menopausal women and 1142 controls of European ancestry, Hunter et al. (12) subsequently reported that four single-nucleotide polymorphisms (SNPs) (rs2420946, rs1219648, rs2981579 and rs11200014) in intron 2 of FGFR2 were associated with breast cancer risk. Interestingly, the five SNPs were in high linkage disequilibrium (LD) in people with European ancestry (all pairwise r 2 . 0.96).
Prior studies have not clearly documented possible relationships between FGFR2 polymorphisms and hormone receptor-defined subsets of breast cancer nor have possible interactions between FGFR2 polymorphisms and breast cancer risk factors been reported. We posited that FGFR2 polymorphisms may contribute to breast cancer susceptibility by acting through hormonal pathways, and we hypothesized that the risk associated with these polymorphisms would vary depending on the hormone receptor status of the breast tumor and on the presence of known reproductive risk factors. To test this hypothesis, we performed genotyping analyses of rs2981582C/T (from Easton et al.), rs1219648A/G and rs2420946C/T (the two most significant SNPs from Hunter et al.) in FGFR2 in a case-control study of 1049 breast cancer cases and 1073 cancer-free controls in a Chinese population.
Materials and methods

Study subjects
This study was approved by the institutional review board of Nanjing Medical University. The hospital-based case-control study included 1058 breast cancer cases and 1078 cancer-free controls, and the process of participant recruitment has been described previously (13) . In brief, incident breast cancer patients were consecutively recruited from the First Affiliated Hospital of Nanjing Medical University, the Cancer Hospital of Jiangsu Province and the Gulou Hospital, Nanjing, China, between January 2004 and May 2007. Exclusion criteria included reported previous cancer history, metastasized cancer from other organs and previous radiotherapy or chemotherapy. All breast cancer cases were newly diagnosed and histopathologically confirmed without restrictions of age or histological type. Cancer-free control women, frequencymatched to the cases on age (±5 years) and residential area (urban or rural), were randomly selected from a cohort of .30 000 participants in a community-based screening program for non-infectious diseases conducted from 2004 to 2006 in the same Jiangsu Province, China. We determined the participants in the cohort as cancer free if they did not report having cancer history at the time Abbreviations: CI, confidence interval; ER, estrogen receptor; FGFR2, fibroblast growth factor receptor 2; LD, linkage disequilibrium; OR, odds ratio; PR, progesterone receptor; SNP, single-nucleotide polymorphism. After providing informed consent, each woman was personally interviewed face-to-face by trained interviewers using a pretested standard questionnaire to obtain information on demographic data, menstrual and reproductive history, environmental exposure history and family history of any cancer in first-degree relatives (parents, siblings and children). The data collection methods were similar for the cases and controls in terms of the investigation of reproductive history including number of births, number of pregnancies, age at menopause and type of menopause. Natural postmenopausal was determined in both cases and controls for women without menstrual flow for .12 months and also no history of sex hormone-related treatment (e.g. surgery, radiation and drug treatment). After the interview, each subject provided 5 ml of venous blood. The estrogen receptor (ER) and progesterone receptor (PR) status of breast cancers was determined from the results of immunohistochemistry examinations contained in the medical records of the hospitals. ER/PR statuses were carried out for the breast cancer cases by established immunohistochemical method of avidin-biotinperoxidase complex assay. Immunoreactivity scoring was performed by evaluating the percentage of cancer cell nuclear staining, and the percentage of staining cells !10% was considered positive.
Genotype analyses
Genomic DNA was isolated from leukocyte pellets from venous blood by proteinase K digestion and followed by phenol-chloroform extraction. The three SNPs (rs2981582C/T, rs1219648A/G and rs2420946C/T) were genotyped on the GenomeLab SNPstream high-throughput 12-plex genotyping platform (Beckman Coulter, Fullerton, CA) following the manufacturer's instructions. This platform uses a single-base pair extension reaction to incorporate two-color fluorescence terminal nucleotides that are detected by a specialized imager (14) .
Ge3notyping was performed without the knowledge of case or control status. Approximately equal numbers of case and control specimens were assayed in each 384-well polymerase chain reaction plate with four blanks and 24 randomly selected duplicates, and the coincidence rate was .99%. Genotyping failed in nine cases (0.85%) and five controls (0.46%) due to DNA quality or quantity; all data from these 14 women were excluded from analyses. Therefore, 1049 breast cancer cases and 1073 controls were included in the final analyses.
Statistical analyses
Differences between cases and controls in demographic characteristics, risk factors and frequencies of FGFR2 variants were evaluated by v 2 tests (for categorical variables) or Student's t-test (for continuous variables). Associations between FGFR2 genotypes and risk of breast cancer were estimated by computing odds ratios (ORs) and their 95% confidence intervals (CIs) from logistic regression analyses with adjustment for age, age at menarche, menopausal status and family history of cancer. Hardy-Weinberg equilibrium was evaluated by a goodness-of-fit v 2 test to compare the observed genotype frequencies with the expected ones among the controls. We used the PHASE 2.0 program to infer haplotype frequencies based on the observed FGFR2 genotypes. To perform tests of possible gene-risk factor interactions for additive models, we implemented bootstrapping using Stata software (version 8.2; StataCorp LP, College 
Results
The 1049 breast cancer cases and 1073 cancer-free controls were similar with regard to age at interview, menopausal status and age at menopause (Table I) . However, cases differed from controls in having an earlier age at menarche, a later age of first live birth, a greater likelihood of a positive family history of any cancer, less parities and more pregnancies. Unusual menopause was also a major risk factor for breast cancer. Among 813 breast cancer cases with known ER and PR status, 364 (44.8%) were positive with both ER and PR and 292 (33.9%) were negative for both. When we stratified ER/PR status by menopause status and age, post-menopausal and aged women were more likely to be ER À /PR À breast cancer patients (Table I) . The genotype distributions of FGFR2 rs2981582C/T, rs1219648A/G and rs2420946C/T polymorphisms in the breast cancer cases and controls are shown in Table II . The call rates of the three SNPs were all .97%. The observed genotype frequencies for these three SNPs were all in agreement with Hardy-Weinberg equilibrium in the controls (P 5 0.974, 0.270 and 0.413 for rs2981582, rs1219648 and rs2420946, respectively).
In the multivariate logistic regression models (Table II) , each of the variant genotypes of FGFR2 rs2981582 was associated with a significantly increased breast cancer risk compared with the wild-type CC genotype (adjusted OR 5 1.31, 95% CI 5 1.08-1.57 for CT; OR 5 1.62, 95% CI 5 1.19-2.20 for TT and OR 5 1.36, 95% CI 5 1.14-1.62 for CT/TT, respectively). Likewise, compared with the rs1219648 AA genotype, there were significantly elevated risks associated with the AG genotype (adjusted OR 5 1.24, 95% CI 5 1.02-1.51), GG genotype (adjusted OR 5 1.56, 95% CI 5 1.19-2.03) and combined AG/GG genotypes (adjusted OR 5 1.31, 95% CI 5 1.09-1.58). ORs were also statistically significantly elevated for the variants of rs2420946 (adjusted OR 5 1.29, 95% CI 5 1.06-1.56 for CT; OR 5 1.44, 95% CI 5 1.09-1.89 for TT and OR 5 1.32, 95% CI 5 1.10-1.59 for CT/TT, respectively). Furthermore, the associations for allele variants were dose dependent for each locus (Trend test: P , 0.001, P 5 0.001 and 0.003 for rs2981582, rs1219648 and rs2420946, respectively). In each dominant model with the Bonferroni correction to adjust for multiple tests, the associations were still statistically significant (P 5 0.009, P 5 0.036 and P 5 0.039 for rs2981582, rs1219648 and rs2420946, respectively). We then performed a combined analysis on the three loci (Table II) . Breast cancer risk was significantly increased in carriers with 3 risk loci compared with those with 0-2 risk loci (adjusted OR 5 1.36, 95% CI 5 1.13-1.62, P 5 0.003).
LD analyses showed that all the three variants of FGFR2 were in LD with each other (r 2 5 0.60 for rs1219648 and rs2981582, In the order of FGFR2 rs2981582, rs1219648 and rs2420946.
FGFR2 polymorphisms and breast cancer r 2 5 0.68 for rs2420946 and rs2981582 and r 2 5 0.89 for rs1219648 and rs2420946). Therefore, we performed haplotype inference on these three polymorphisms. As shown in Table III , three common haplotypes were identified to account for .95% of all haplotypes constructed by these three SNPs. Compared with the most common haplotype CAC, the TGT haplotype was associated with a 1.27-fold (95% CI 5 1.11-1.45) elevated risk of breast cancer. In the stratified analysis Table IV , there were no obvious evidence of the association between the combined effects of the 3 risk loci and breast cancer risk among different subgroups stratified by age, age at menarche, age at first live birth and family history of cancer. However, the elevated risk was slightly more evident among subjects with ER þ / PR þ (OR 5 1.62, 95% CI 5 1.26-2.09) and premenopausal patients (OR 5 1.60, 95% CI 5 1.23-2.07). Furthermore, the P value for heterogeneity test between groups of different menopausal status was 0.08, indicating the potential heterogeneity among the different levels. Therefore, a gene-menstrual interaction analysis was performed (Table V) , and there was a statistically significant additive interaction between the number of risk loci and menopausal status on breast cancer risk (P for additive interaction 5 0.037).
Discussion
In this case-control study of sporadic breast cancer in Chinese women, we found that the variant genotypes rs2981582C/T, rs1219648A/G and rs2420946C/T of FGFR2 were all significantly associated with increased breast cancer risk. The associations appeared to be strongest in premenopausal women and those with ER/ PR-positive tumors indicating that these variant genotypes may be involved in the etiology of breast cancer through pathways related to estrogen and/or progesterone. The Breast Cancer Association Consortium genome-wide association study has identified FGFR2 rs2981582 in intron 2 as the most significant breast cancer risk locus (7). Hunter et al. (12) conducted another independent genome-wide association study and identified several novel low-penetrance loci of FGFR2 (rs1219648A/G and rs2420946C/T) that were associated with sporadic post-menopausal breast cancer susceptibility in a group of women who were predominantly of European origin. However, premenopausal women were not included. During the manuscript was in preparation, Garcia-Closas et al. (15) conducted a stratified analysis on breast cancer risk and FGFR2 rs2981582 by clinical and pathological characteristics and found that the effect of rs2981582 was stronger in ER/PR-positive patients. However, most of the participants of the Breast Cancer Association Consortium provided ER/PR information was of European origin, and only 888 breast cancer cases and 744 controls were Thai and American Japanese. Furthermore, LD patterns are quite different for European and Chinese populations (all pairwise r 2 . 0.96 for the three SNPs of European ancestry, but r 2 5 0.649 for rs2981582 and rs1219648 in Chinese in the present study). As shown in Figure 1 , the SNPs of FGFR2 (rs2981582C/T, rs1219648A/G and rs2420946C/T) are in the same block in Europeans, whereas this region is divided into two blocks in Chinese. Although it seemed we found similar genetic markers in Europeans (7, 12) and in Chinese, a functional study showed that the causal SNP could be rs2981578 (all pairwise r 2 . 0.80 with rs2981582, rs1219648 and rs2420946 in European ancestry) (16), which might not be applicable in Chinese (r 2 FGFR2 polymorphisms and breast cancer rs1219648 and rs2420946, respectively). In Chinese populations, fine mapping and/or functional characterizations were warranted to determine the causal variants related to breast cancer risk. FGFR2 is amplified and overexpressed in 10% of human breast cancers (10) , but different splicing isoforms may also lead to differential transforming activities in human mammary epithelial cells (12) . Therefore, it is biologically plausible that genetic variants in intron 2 of FGFR2 or nearby may be important in breast cancer etiology, although the detailed mechanism needs to be explored further.
It has long been hypothesized that high levels of endogenous sex hormones, especially estrogens, may increase breast cancer risk (17) . Further, post-menopausal hormone replacement therapy with estrogen/progesterone combinations is associated with greater risk of breast cancer than use of estrogen alone (18) . Menstrual and reproductive factors, including early age at menarche and later age at first birth, which might be indicators of endogenous sex hormones levels, are recognized breast cancer risk factors (3, 19, 20) . For example, menarche can induce proliferation of breast cells (19) , whereas pregnancy can induce differentiation of breast tissue through mediating levels of endogenous sex hormones (21) (22) (23) . In premenopausal women, the ovaries are the predominant source of serum estrogen, and exposure is much higher than for post-menopausal women (23) .
FGFR2 has been reported to be significantly more likely to be upregulated in ERa-positive breast tumors compared with ERanegative breast tumors (24) . Keratinocyte growth factor and keratinocyte growth factor receptor (KGFR, FGFR2IIIb) act as growth factors mediating estrogen action, and their expression, which is ER dependent, significantly correlates with an antiapoptotic role in human breast cancer (25) . Furthermore, in mouse mammary glands, KGFR expression is determined by the ratio of estradiol and progesterone, indicating a mechanism through which these hormones can cooperate to optimize their growth-promoting effects (26) . Our findings that the combined effects of FGFR2 variants are greater in ER-positive and/or PR-positive breast cancer and FGFR2 variants interact with menopausal status appear to be consistent with an activity that is hormonally mediated. Further studies are warranted to explore the role of FGFR2 variants in mediating apoptosis, proliferation and differentiation of breast cells, together with estrogen and progesterone.
In conclusion, this is the first study to demonstrate that genetic variants in intron 2 of FGFR2 are significantly associated with increased risk of breast cancer in Chinese women, possibly associated with the status of hormone receptors and the reproductive history of women. Considering the different LD block patterns among populations, we called for a fine mapping of this region in different populations. 
